中国2021-2024年人乳头瘤病毒疫苗上市后疑似预防接种异常反应监测分析
严重AEFI和严重罕见疫苗反应报告发生率分别为0.13/10万剂和0.05/10万剂,未发现新的或具有临床意义的安全问题。
要点
- HPV疫苗总AEFI报告发生率为14.61/10万剂,以常见疫苗反应为主。
- 严重AEFI报告发生率0.13/10万剂,严重罕见疫苗反应0.05/10万剂。
- 9-12岁、13-17岁、18-30岁、31-46岁AEFI报告发生率分别为15.01、16.37、14.00、14.77/10万剂。
核心结论
- 2021-2024年中国上市HPV疫苗的免疫安全性良好,严重疫苗反应极罕见,未发现新的或具有临床意义的安全问题。
研究设计与样本
- 利用中国免疫规划信息系统(CNIIS)获取2021-2024年所有HPV疫苗AEFI报告及接种剂次数,采用描述性流行病学方法分析AEFI报告特征和报告发生率(RI)。
主要发现
- 9-12岁、13-17岁、18-30岁、31-46岁人群AEFI报告发生率分别为15.01、16.37、14.00、14.77/10万剂。
- 二价、四价和九价HPV疫苗AEFI报告发生率分别为8.49、12.65和20.50/10万剂。
- 大多数AEFI报告为常见疫苗反应:注射部位反应(红肿/肿胀)报告发生率为6.31/10万剂,全身反应(发热)为3.71/10万剂。
- 罕见疫苗反应报告发生率为0.49/10万剂,以过敏性皮疹最多见;严重AEFI和严重罕见疫苗反应报告发生率分别为0.13/10万剂和0.05/10万剂。
临床怎么用
- 监测数据支持中国上市HPV疫苗在女性中的安全性,可为接种服务中医护人员向受种者解释常见反应和严重反应风险提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) vaccine has been authorized by the National Medical Products Administration for marketing in China since 2016. This study analyzed the adverse events following immunization (AEFI) with all HPV vaccines available in China during 2021-2024: three imported and two domestic HPV vaccines, which were all non-program vaccines approved for females only during the study period. METHODS: We obtained all AEFI reports and numbers of HPV vaccine doses administered during 2021-2024 from the Chinese National Immunization Information System (CNIIS). We used descriptive epidemiological methods to analyze characteristics and reporting incidence (RI) of HPV vaccine AEFI reports. RESULTS: During the study period, 163.57 million doses of HPV vaccine were administered and 23,890 HPV vaccine AEFI were reported, for an overall RI of 14.61 AEFI reports per 100,000 doses. Respective AEFI RIs for 9-12-years-old, 13-17-years-olds, 18-30-years-olds, and 31-46-years-olds were 15.01, 16.37, 14.00, and 14.77 per 100,000 doses administered. For bivalent, quadrivalent and 9-valent HPV vaccines, respective RIs were 8.49, 12.65, and 20.50 per 100,000 doses. Most AEFI reports were for common vaccine reactions - injection site reactions (redness/swelling, 6.31 reports per 100,000 doses) and systematic reactions (fever, 3.71 reports per 100,000 doses). The reporting incidence of rare vaccine reactions was 0.49 per 100,000 doses administered, with allergic rash most frequently reported. RIs of serious AEFI and serious rare vaccine reactions were 0.13 and 0.05 per 100,000 doses administered, respectively. CONCLUSIONS: The immunization safety profile of HPV vaccines available in China during 2021-2024 was acceptable based on this national AEFI data analysis. Serious adverse vaccine reactions were extremely rare; no new or clinically meaningful safety concerns were found.
引用
- Zhang L, Li K, Li Y, et al. Adverse events following immunization with human papillomavirus vaccine: post-marketing surveillance in China, 2021-2024. Vaccine. 2026. PMID: 42296833. doi:10.1016/j.vaccine.2026.128826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。